ArticleTrials2024

Neoadjuvant therapy of sequential TACE, camrelizumab, and apatinib for single huge hepatocellular carcinoma (NEO-START): study protocol for a randomized controlled trial.

Yun Hao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.